Truist lowered the firm’s price target on Teleflex (TFX) to $200 from $227 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology.

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...